OncoSec Medical

OncoSec Medical

Employees:
40
Market Cap:
$80.32 million
Revenue:
$0.0
5 Year Trend:
0.0%
Net Income:
$-25.14 million
NASDAQ:
ONCS

OncoSec Medical

Employees:
40
Market Cap:
$80.32 million
Revenue:
$0.0
5 Year Trend:
0.0%
Net Income:
$-25.14 million
NASDAQ:
ONCS
  • Dec 12 at 7:50 PM
    #DYK ImmunoPulseIL-12 + #pembrolizumab in anti-PD-1 non-responsive patients led to a 50% best overall response rate: http://bit.ly/2C9pjIi
  • Nov 14 at 4:51 PM
    Were proud of the progress weve made to advance OncoSecs science and technology. Check out our recent scientific posters from #SITC2017 at http://bit.ly/1KKQHcq
  • Nov 8 at 1:57 PM
    We are pleased to announce updated data from our combination study (Phase 2 OMS-I102) of ImmunoPulse IL-12 in combination with pembrolizumab, which demonstrated a 57% Progression Free Survival Rate at 15 months in Predicted Anti-PD-1 Non-Responder Melanoma Patients! "Overall, the Phase 2 trial results, including progression free survival beyond two years in multiple patients, duration of response, best overall response rate, and tolerability of the combination, provide a strong and consistent theme across multiple endpoints, underscoring the promise of ImmunoPulse IL-12 plus pembrolizumab as a viable treatment option for patients diagnosed with metastatic melanoma," said Dr. Alain Algazi, Lead Trial Investigator, Associate Professor, Department of Medicine (Hematology/Oncology), at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center. These results will be presented in an oral presentation on Friday, November 10th, 2017 at the Society for Immunotherapy of Cancer Annual Meeting. Click here for more details: http://bit.ly/2zrapOu
  • Oct 30 at 9:38 PM
    Breast Cancer affects many lives. Talk to your doctor about screening, family history and prevention today! #breastcancerawarenessmonth

Dec 12, 7:50 PM

#DYK ImmunoPulseIL-12 + #pembrolizumab in anti-PD-1 non-responsive patients led to a 50% best overall response rate: http://bit.ly/2C9pjIi

Nov 14, 4:51 PM

Were proud of the progress weve made to advance OncoSecs science and technology. Check out our recent scientific posters from #SITC2017 at http://bit.ly/1KKQHcq

Nov 8, 1:57 PM

We are pleased to announce updated data from our combination study (Phase 2 OMS-I102) of ImmunoPulse IL-12 in combination with pembrolizumab, which demonstrated a 57% Progression Free Survival Rate at 15 months in Predicted Anti-PD-1 Non-Responder Melanoma Patients! "Overall, the Phase 2 trial results, including progression free survival beyond two years in multiple patients, duration of response, best overall response rate, and tolerability of the combination, provide a strong and consistent theme across multiple endpoints, underscoring the promise of ImmunoPulse IL-12 plus pembrolizumab as a viable treatment option for patients diagnosed with metastatic melanoma," said Dr. Alain Algazi, Lead Trial Investigator, Associate Professor, Department of Medicine (Hematology/Oncology), at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center. These results will be presented in an oral presentation on Friday, November 10th, 2017 at the Society for Immunotherapy of Cancer Annual Meeting. Click here for more details: http://bit.ly/2zrapOu

Oct 30, 9:38 PM

Breast Cancer affects many lives. Talk to your doctor about screening, family history and prevention today! #breastcancerawarenessmonth

2 jobs at OncoSec Medical

Jobs in